Accelerate Diagnostics (NASDAQ:AXDX) issued its earnings results on Thursday, February 15th. The medical research company reported ($0.27) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.05, Bloomberg Earnings reports. Accelerate Diagnostics had a negative return on equity of 55.26% and a negative net margin of 1,520.99%. The firm had revenue of $2.10 million for the quarter.
Accelerate Diagnostics (NASDAQ AXDX) traded down $0.20 during midday trading on Friday, reaching $25.75. The company had a trading volume of 192,540 shares, compared to its average volume of 301,512. Accelerate Diagnostics has a 1 year low of $16.75 and a 1 year high of $30.45. The firm has a market cap of $1,410.00, a P/E ratio of -22.20 and a beta of 2.19.
Several research firms have commented on AXDX. BidaskClub upgraded Accelerate Diagnostics from a “hold” rating to a “buy” rating in a research report on Thursday. Zacks Investment Research upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Wednesday. BTIG Research reaffirmed a “hold” rating on shares of Accelerate Diagnostics in a research note on Sunday, February 18th. Finally, ValuEngine downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $33.00.
In related news, Director Jack W. Schuler bought 20,000 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was acquired at an average cost of $24.95 per share, with a total value of $499,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 50.00% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Accelerate Diagnostics (NASDAQ:AXDX) Releases Earnings Results, Beats Estimates By $0.05 EPS” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://ledgergazette.com/2018/02/24/accelerate-diagnostics-axdx-issues-quarterly-earnings-results-beats-estimates-by-0-05-eps.html.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.